VCIM
CTMX icon

Velan Capital Investment Management’s CytomX Therapeutics CTMX Stock Holding History

Velan Capital Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.54M Buy
540,000
+460,000
+575% +$2.33M 1.59% 17
2025
Q4 		$341K Hold
80,000
– – 0.2% 30
2025
Q3 		$255K Buy
80,000
+5,000
+7% +$11.3K 0.24% 27
2025
Q2 		$170K Hold
75,000
– – 0.17% 30
2025
Q1 		$47.7K Buy
75,000
+40,000
+114% +$31K 0.05% 39
2024
Q4 		$36K Buy
+35,000
New +$37.7K 0.03% 39

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Velan Capital Investment Management's CTMX Position: Q1 2026 in Review

Velan Capital Investment Management increased its CytomX Therapeutics (CTMX) stake by 575% in Q1 2026, buying an estimated $2.33M and bringing the position to 540,000 shares worth $2.54M. The position accounts for 1.59% of the portfolio, ranked #17.

Velan Capital Investment Management first reported a position in CTMX in Q4 2024 and has held it in 6 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Velan Capital Investment Management held 540,000 shares of CytomX Therapeutics worth $2.54M as of Q1 2026.
  • Velan Capital Investment Management bought 460,000 CytomX Therapeutics shares in Q1 2026, an estimated $2.33M.
  • CytomX Therapeutics made up 1.59% of Velan Capital Investment Management's portfolio in Q1 2026, its #17 holding.
  • Velan Capital Investment Management first reported a position in CytomX Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.